Skip to content

Therapy with low level Laser therapy in patients under methadone maintenance treatment

Therapeutic effects of low level Laser therapy in reducing anxiety, depression, and substance abuse craving in patients under methadone maintenance treatment Compared with the control group

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210502051162N1
Enrollment
80
Registered
2021-08-25
Start date
2021-09-06
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Addiction. Opioid related disorders

Interventions

Intervention 1: Intervention group: This group is treated with low level Laser therapy for 2 weeks and 3 sessions per week. The time of exposure to light is 4 minutes in both places of the forehead. T

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients on methadone treatment who have been in treatment for at least three months Age over 18 years Admission will be regardless of gender or ethnicity

Exclusion criteria

Exclusion criteria: Patients treated with other methods of quitting addiction Methadone maintenance treatment less than 3 months We excluded patients who were not between the ages of 18 and 60 Anyone with a history of psychosis and other psychiatric disorders (bipolar, etc.) A history of violent behavior, a history of moving or attempting suicide in the past

Design outcomes

Primary

MeasureTime frame
Anxiety rate. Timepoint: After the end of treatment and one month after the last treatment. Method of measurement: HAM-A Through a questionnaire (Hamilton Anxiety measure scale).;Depression rate. Timepoint: After the end of treatment and one month after the last treatment. Method of measurement: HAM-D Through a questionnaire (Hamilton depression measure scale).;Opioid craving scale. Timepoint: After the end of treatment and one month after the last treatment. Method of measurement: OCS Through a questionnaire (opioid craving scale).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHelia Helali

Shahid Beheshti University of Medical Sciences

heliahelali1990@yahoo.com+98 21 2205 7254

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 6, 2026